新型コロナウイルス感染症（COVID-19）のパンデミックは、人々の移動を制限し、家の中に閉じ込め、悲しみや孤独という形で深刻なトラウマやストレスを与え、個人の精神的な健康にも影響を与えています。その結果、多くの国で、人々はうつ病や不安症などの病状に直面しています。精神疾患の治療に大きな可能性を持つ幻覚剤市場は、近い将来、より多くの需要が見込まれるため、大規模な投資が行われる可能性があります。
世界の幻覚剤市場は2020年に38億USドルと評価されました。幻覚剤市場は、世界中でうつ病やその他の精神障害の有病率が高まっているため、急速に成長しています。環境ストレスへの対応、生活の質の向上などのニーズが、幻覚剤市場の推進力として機能しています。幻覚剤依存症の治療は、幻覚剤市場の成長を後押しすることが期待されています。
さらに、世界中で幻覚剤治療カテゴリーの研究開発活動が活発化しており、産業の発展を大きく支えています。企業は、これらの製品に関連する副作用を最小限に抑えた新しい幻覚剤治療分子を開発するための研究開発活動に積極的に投資しています。これにより、予測期間中の幻覚剤業界のさらなる成長のための強力なプラットフォームが構築されました。
北アメリカ地域が幻覚剤市場を独占しています。北アメリカでは、うつ病やストレスなどの精神疾患に対する意識の高まりが、幻覚剤市場の成長を後押しすると期待されています。経済的ストレス、家族向けのサポート構造の崩壊、環境条件の悪化などの社会的要素は、予測期間中の市場成長を加速するとさらに推定されます。
目次
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Psychedelic Drugs Market Product Outlook
4. Global Psychedelic Drugs Market: An Analysis
4.1 Market Size, By Value, Year 2016-2026
4.2 COVID-19 Impact on Psychedelic Drugs Market
5. Global Psychedelic Drugs Market Segmentation By Route of Administration (By Value)
5.1 Competitive Scenario of Global Psychedelic Drugs Market: By Route of Administration
5.2 Oralñ Market Size and Forecast (2016-2026)
5.3 Intranasalñ Market Size and Forecast (2016-2026)
5.4 Intravenousñ Market Size and Forecast (2016-2026)
5.5 Othersñ Market Size and Forecast (2016-2026)
6. Global Psychedelic Drugs Market Segmentation By Drug (By Value)
6.1 Competitive Scenario of Global Psychedelic Drugs Market: By Drug
6.2 Gamma-hydroxybutyrateñ Market Size and Forecast (2016-2026)
6.3 Ketamineñ Market Size and Forecast (2016-2026)
6.4 Psilocybinñ Market Size and Forecast (2016-2026)
6.5 MDMAñ Market Size and Forecast (2016-2026)
6.6 Othersñ Market Size and Forecast (2016-2026)
7. Global Psychedelic Drugs Market Segmentation By Distribution Channel (By Value)
7.1 Competitive Scenario of Global Psychedelic Drugs Market: By Distribution Channel
7.2 Hospitals Pharmacyñ Market Size and Forecast (2016-2026)
7.3 Retail Pharmacyñ Market Size and Forecast (2016-2026)
7.4 Online Pharmacyñ Market Size and Forecast (2016-2026)
8. Global Psychedelic Drugs Market: Regional Analysis
8.1 Competitive Scenario of Global Psychedelic Drugs Market: By Region
9. North America Psychedelic Drugs Market: An Analysis (2016-2026)
9.1 North America Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
9.2 North America Psychedelic Drugs Market ñ Prominent Companies
9.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)
9.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)
9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)
9.6 North America Psychedelic Drugs Market: Country Analysis
9.7 Market Opportunity Chart of North America Psychedelic Drugs Market - By Country, By Value (Year-2026)
9.8 Competitive Scenario of North America- By Country
9.9 United States Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
9.10 United States Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
9.11 Canada Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
9.12 Canada Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10. Europe Psychedelic Drugs Market: An Analysis (2016-2026)
10.1 Europe Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.2 Europe Psychedelic Drugs Market ñ Prominent Companies
10.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)
10.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)
10.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)
10.6 Europe Psychedelic Drugs Market: Country Analysis
10.7 Market Opportunity Chart of Europe Psychedelic Drugs Market - By Country, By Value (Year-2026)
10.8 Competitive Scenario of Europe- By Country
10.9 Germany Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.10 Germany Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.11 United Kingdom Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.12 United Kingdom Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.13 France Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.14 France Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.15 Italy Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.16 Italy Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
10.17 Spain Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
10.18 Spain Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
11. Asia Pacific Psychedelic Drugs Market: An Analysis (2016-2026)
11.1 Asia Pacific Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.2 Asia Pacific Psychedelic Drugs Market ñ Prominent Companies
11.3 Market Segmentation By Drug (Gamma-hydroxybutyrate, MDMA, Ketamine, Psilocybin and Others)
11.4 Market Segmentation By Route of Administration (Oral, Intranasal, Intravenous and Others)
11.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy)
11.6 Asia Pacific Psychedelic Drugs Market: Country Analysis
11.7 Market Opportunity Chart of Asia Pacific Psychedelic Drugs Market - By Country, By Value (Year-2026)
11.8 Competitive Scenario of Asia Pacific- By Country
11.9 China Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.10 China Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
11.11 India Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.12 India Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
11.13 Japan Psychedelic Drugs Market: Size and Forecast (2016-2026), By Value
11.14 Japan Psychedelic Drugs Market Segmentation By Drug, Route of Administration and Distribution Channel.
12. Global Psychedelic Drugs Market Dynamics
12.1 Global Psychedelic Drugs Market Drivers
12.2 Global Psychedelic Drugs Market Restraints
12.3 Global Psychedelic Drugs Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.1.1 Market Attractiveness Chart of Global Psychedelic Drugs Market ñ By Drug, By Value (Year-2026)
13.1.2 Market Attractiveness Chart of Global Psychedelic Drugs Market ñ By Route of Administration, By Value (Year-2026)
13.1.3 Market Attractiveness Chart of Global Psychedelic Drugs Market ñ By Distribution Channel, By Value (Year-2026)
13.1.4 Market Attractiveness Chart of Global Psychedelic Drugs Market ñ By Region, By Value (Year-2026)
13.2 Strategic Analysis
13.2.1 Product approvals
13.2.2 Mergers and Acquisitions
14. Competitive Landscape
14.1 Market Share Analysis
15. Psychedelic Drugs Pipeline Development
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 Johnson & Johnson
16.2 Pfizer
16.3 AbbVie Inc.
16.4 Jazz Pharmaceuticals
16.5 NUMINUS WELLNESS INC WS
16.6 COMPASS Pathways PLC
16.7 Mindset Pharma
16.8 Mydecine Innovations Group
16.9 TRYP Therapeutics Inc
16.10 MindMed
16.11 Cybin Inc.
